{"id":410517,"date":"2021-01-07T09:49:41","date_gmt":"2021-01-07T14:49:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410517"},"modified":"2021-01-07T09:49:41","modified_gmt":"2021-01-07T14:49:41","slug":"dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/","title":{"rendered":"DLA Piper advises Histogen in its US$14 million upsized public offering"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Jan. 7, 2021<\/span> \/PRNewswire\/ —\u00a0DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO),\u00a0a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00<\/span> per share.<\/p>\n

“We were pleased to bring our extensive experience helping life sciences companies access the capital markets to close this transaction. This funding will allow Histogen to expand its research and development efforts as it continues to advance innovative therapeutic solutions,” said Larry Nishnick<\/span><\/a>, the DLA Piper partner who led the firm’s deal team. <\/p>\n

In addition to Nishnick (San Diego<\/span>), the DLA Piper team advising Histogen included partner Patrick O’Malley<\/span><\/a> (San Diego<\/span>) and associate Kathryn Fortin<\/span><\/a> (San Diego<\/span>). <\/p>\n

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.<\/p>\n

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients.\u00a0Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.\u00a0 <\/p>\n

\n About DLA Piper
<\/b>DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe<\/span>, the Middle East<\/span>, Africa<\/span> and Asia Pacific<\/span>, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com<\/a><\/p>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering-301202841.html<\/a><\/p>\n

SOURCE DLA Piper<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Jan. 7, 2021 \/PRNewswire\/ —\u00a0DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO),\u00a0a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00 per share. “We were pleased to bring our extensive experience helping life sciences companies access the capital markets to close this transaction. This funding will allow Histogen to expand its research and development efforts as it continues to advance innovative therapeutic solutions,” … <\/p>\n

Continue reading “DLA Piper advises Histogen in its US$14 million upsized public offering”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410517","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDLA Piper advises Histogen in its US$14 million upsized public offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DLA Piper advises Histogen in its US$14 million upsized public offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Jan. 7, 2021 \/PRNewswire\/ —\u00a0DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO),\u00a0a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00 per share. “We were pleased to bring our extensive experience helping life sciences companies access the capital markets to close this transaction. This funding will allow Histogen to expand its research and development efforts as it continues to advance innovative therapeutic solutions,” … Continue reading "DLA Piper advises Histogen in its US$14 million upsized public offering"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T14:49:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH40103&sd=2021-01-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DLA Piper advises Histogen in its US$14 million upsized public offering\",\"datePublished\":\"2021-01-07T14:49:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/\"},\"wordCount\":335,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH40103&sd=2021-01-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/\",\"name\":\"DLA Piper advises Histogen in its US$14 million upsized public offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH40103&sd=2021-01-07\",\"datePublished\":\"2021-01-07T14:49:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH40103&sd=2021-01-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH40103&sd=2021-01-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DLA Piper advises Histogen in its US$14 million upsized public offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DLA Piper advises Histogen in its US$14 million upsized public offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"DLA Piper advises Histogen in its US$14 million upsized public offering - Market Newsdesk","og_description":"PR Newswire NEW YORK, Jan. 7, 2021 \/PRNewswire\/ —\u00a0DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO),\u00a0a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00 per share. “We were pleased to bring our extensive experience helping life sciences companies access the capital markets to close this transaction. This funding will allow Histogen to expand its research and development efforts as it continues to advance innovative therapeutic solutions,” … Continue reading \"DLA Piper advises Histogen in its US$14 million upsized public offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T14:49:41+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH40103&sd=2021-01-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DLA Piper advises Histogen in its US$14 million upsized public offering","datePublished":"2021-01-07T14:49:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/"},"wordCount":335,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH40103&sd=2021-01-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/","name":"DLA Piper advises Histogen in its US$14 million upsized public offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH40103&sd=2021-01-07","datePublished":"2021-01-07T14:49:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH40103&sd=2021-01-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH40103&sd=2021-01-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DLA Piper advises Histogen in its US$14 million upsized public offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410517"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410517\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}